ELEVAI LABS, INC. (NASDAQ: ELAB) (“Elevai” or the “Company”), a
medical aesthetic company specializing in physician-dispensed skin
care, is pleased to announce that it has signed an international
distribution agreement with ILIA International Ltd. (“ILIA”)
covering the country of Taiwan.
ILIA is a Taiwan-based sales and marketing distributor of luxury
skincare brands utilizing novel, cutting-edge technologies. Under
the agreement, ILIA will have exclusive rights to distribute
ELEVAI’s patented skincare products throughout Taiwan. ILIA’s
near-term sales strategy will be to strategically distribute ELEVAI
products to their customers in the country.
Chris Kraneiss, Chief Commercial Officer of Elevai Labs,
Inc. commented:
“It is with great pleasure that I announce the signing of ILIA
International Ltd. as our exclusive distributor in Taiwan. From my
past dealings in the region, I know that ILIA is very well
respected in the Taiwanese market and is one of the leading
aesthetic distributors in that territory. Exosome-based beauty has
some of its earliest roots in the Asian region, and it is a
testament to our quality, purity, proprietary technology, and
advanced formulations that we have had such a rapid uptake on the
continent. We believe that with this agreement ELEVAI will become
one of the leading exosome providers in Taiwan, and that ILIA’s
access to all leading aesthetic practices and clinics will set us
on the proper course.”
Cordelia Huang, Managing Director of ILIA International
Ltd., Taiwan commented:
“We are proud to be a part of this opportunity to introduce
cutting-edge skincare products from ELEVAI Labs to our high-end
medical aesthetics clients in Taiwan. We have strong confidence in
ELEVAI’s E-series skincare products’ efficacy in enhancing health
and beauty and expect the brand to prevail in this region.”
Demand for Prestige in Taiwan:
According to GLG, a financial and global information services
company, beauty trends in Taiwan mirror many of the attributes of
Japan’s robust market, but with stronger growth. In Taiwan, the
prestige side of the industry leads at 60% of the market share,
with mass products taking the other 40%,1 illustrating outsized
demand for higher-end products compared to the US market, which is
closer to 50/502.
Regional Insights:
Asia-Pacific’s regional growth is set to markedly outperform the
rest of the world for high-end skin and hair products due to a
confluence of positive trends, including rising disposable income
in several countries, increased urbanization, and growing awareness
of personal grooming3.
The size of Asia-Pacific’s prestige skincare and luxury haircare
markets currently sits at $2.6 Billion4 and $10.4 Billion5,
respectively. Combined, these markets currently represent $13
Billion in current annual turnover and is predicted to reach $20.6
Billion by 2030.
The Asia-Pacific market is also set to outperform the rest of
the world in terms of growth. Asia’s prestige skincare market is
projected to grow at 9.9% over the next 5 years6 while the world
market averages 3.9%7. Within the luxury haircare space,
Asia-Pacific is set for yearly growth is 8.9%8 for the next 6 years
while the world market averages 5.9%9.
About ILIA International
Limited
ILIA specializes in full-scale sales and
marketing of luxury skincare brands composed of novel technology,
best-of-class aesthetics, and therapeutics applications in
anti-aging, skin longevity, and cell therapy, particularly in the
emerging field of exosome solutions. The company’s core strength is
addressing the unmet demands from the medical physician-dispensed
and consumer-driven markets.
About ELEVAI Labs
ELEVAI Labs, Inc. (NASDAQ: ELAB) is a medical aesthetics company
developing cutting-edge physician-dispensed skin care applications.
The Company solves unmet needs in the medical aesthetics space
through a combination of cutting-edge science-driven and
next-generation consumer applications. ELEVAI Labs develops topical
aesthetic skin care cosmetic products for the physician-dispensed
market, with a focus on leveraging a proprietary stem cell exosome
technology. For more information visit www.elevaiskincare.com.
Forward-Looking Statements
Certain statements made in this press release are
“forward-looking statements” within the meaning of the “safe
harbor” provisions of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements may be identified using words
such as “anticipate,” “believe,” “expect,” “estimate,” “plan,”
“outlook,” “anticipate,” and “project” and other similar
expressions that predict or indicate future events or trends or
that are not statements of historical matters. These
forward-looking statements reflect the current analysis of existing
information and are subject to various risks and uncertainties. As
a result, caution must be exercised in relying on forward-looking
statements. Due to known and unknown risks, actual results may
differ materially from the Company’s expectations or projections.
The following factors, among others, could cause actual results to
differ materially from those described in these forward-looking
statements: (i) the failure to meet projected research &
development and production targets; (ii) changes in applicable laws
or regulations; (iii) acceptance of our products by consumers and
the medical professionals; (iv) increased competition; (v) market
conditions; and (vi) other risks and uncertainties described
herein, as well as those risks and uncertainties discussed from
time to time in our annual and quarterly reports and other public
filings filed with the Securities and Exchange Commission (the
“SEC”) and publicly available on the SEC’s website at www.sec.gov.
Any forward-looking statement made by us in this press release is
based only on information currently available to the Company and
speaks only as of the date on which it is made. The Company
undertakes no obligation to publicly update any forward-looking
statement, whether written or oral, that may be made from time to
time, whether because of new information, future developments, or
otherwise, except as required by law.
Media & Product Contact:Brenda Buechler,
CMOcontact@elevailabs.com
Investor Relations Contact:Tyler Troup,
Circadian Group IRIR@elevailabs.com
1 https://glginsights.com/articles/china-beauty-industry-apac/2
https://www.premiumbeautynews.com/en/make-up-drives-sales-of-mass-and,22478#:~:text=U.S.%20prestige%20beauty%20industry%20sales,IRI%20and%20The%20NPD%20Group
3
https://www.grandviewresearch.com/industry-analysis/luxury-hair-care-market
4
https://www.statista.com/outlook/emo/luxury-goods/prestige-cosmetics-fragrances/prestige-skin-care/asia]
5
https://markets.businessinsider.com/news/stocks/luxury-hair-care-market-size-worth-31-50-billion-by-2027-cagr-5-9-grand-view-research-inc-10295771496
https://www.statista.com/outlook/emo/luxury-goods/prestige-cosmetics-fragrances/prestige-skin-care/asia
7
https://www.statista.com/outlook/cmo/luxury-goods/prestige-cosmetics-fragrances/prestige-skin-care/worldwide#:~:text=The%20revenue%20generated%20in%20the,US%246%2C722m%20in%202024
8
https://www.giiresearch.com/report/kbv1403637-asia-pacific-luxury-hair-care-market-size-share.html9
https://markets.businessinsider.com/news/stocks/luxury-hair-care-market-size-worth-31-50-billion-by-2027-cagr-5-9-grand-view-research-inc-1029577149
Elevai Labs (NASDAQ:ELAB)
過去 株価チャート
から 8 2024 まで 9 2024
Elevai Labs (NASDAQ:ELAB)
過去 株価チャート
から 9 2023 まで 9 2024